stockportfolio.pro
Viridian Therapeutics, Inc. (VRDN)
Healthcare · Biotechnology · NasdaqCM
Viridian Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.48M | $4.00M | $8.39M | $4.46M | $1.05M | $2.96M | $1.77M | $314,000 | $302,000 | $70.85M |
| Gross profit | $929,000 | — | — | — | — | — | — | — | — | — |
| Net income | $-17.27M | $-26.51M | $-32.70M | $-41.87M | $-110.72M | $-79.41M | $-129.87M | $-237.73M | $-269.95M | $-342.60M |
| Net margin | -496.8% | -662.3% | -390.0% | -938.6% | -10544.3% | -2680.2% | -7329.2% | -75711.5% | -89387.1% | -483.6% |
Source: Viridian Therapeutics, Inc. SEC filings (10-K). 13 years of history available in the interactive view.
Explore 13 years of Viridian Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track VRDN in your portfolio →
Viridian Therapeutics, Inc. financial history by metric
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Viridian Therapeutics, Inc. — frequently asked questions
What is Viridian Therapeutics, Inc.'s revenue?
Viridian Therapeutics, Inc. (VRDN) reported revenue of $70.85M for fiscal year 2025, up 23359.9% from the prior year, according to its SEC filings.
Is Viridian Therapeutics, Inc. profitable?
No — VRDN reported a net loss of $-342.60M in fiscal 2025.
What is VRDN's P/E ratio?
Viridian Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Viridian Therapeutics, Inc. growing?
VRDN's revenue grew at roughly 132.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Viridian Therapeutics, Inc. have?
As of fiscal year 2025, VRDN carried roughly $49.94M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Viridian Therapeutics, Inc.'s market cap?
Viridian Therapeutics, Inc. (VRDN) has a market capitalization of about $1.78B, based on the latest data in our nightly-refreshed cache.
When does Viridian Therapeutics, Inc.'s fiscal year end?
VRDN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Viridian Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.